The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

CULVER CITY, Calif., April 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for ...

ImmunityBio (IBRX) announced that it has executed financing to provide further working capital and support its ongoing business operations. The ...

ImmunityBio, Inc.’s IBRX share price has dipped by 6.07%, which has investors questioning if this is right time to buy.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

With a permanent J-code (J9028) awarded in January 2025, ImmunityBio’s Q1 2025 ANKTIVA unit sales volume grew 150% over unit sales volume in Q4 2024. For the three-month period ended March 31 ...